BioNTech Phase 3 trial of variant-adapted BNT162b2 COVID vaccine recruitingSep 30Weekly roundup, 7 itemsatirmociclibberobenatide
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studiesAug 21Weekly roundup, 7 itemsBioNTech SEPenbraya
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.
Sign inSign in